NZ708506A - Methods of treating bladder cancer - Google Patents

Methods of treating bladder cancer

Info

Publication number
NZ708506A
NZ708506A NZ708506A NZ70850611A NZ708506A NZ 708506 A NZ708506 A NZ 708506A NZ 708506 A NZ708506 A NZ 708506A NZ 70850611 A NZ70850611 A NZ 70850611A NZ 708506 A NZ708506 A NZ 708506A
Authority
NZ
New Zealand
Prior art keywords
bladder cancer
methods
treating bladder
taxane
medicament
Prior art date
Application number
NZ708506A
Other languages
English (en)
Inventor
Patrick Soon-Shiong
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45067028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ708506(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NZ708506A publication Critical patent/NZ708506A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heat Treatment Of Steel (AREA)
NZ708506A 2010-06-02 2011-05-20 Methods of treating bladder cancer NZ708506A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39680010P 2010-06-02 2010-06-02
US201161449513P 2011-03-04 2011-03-04
NZ604029A NZ604029A (en) 2010-06-02 2011-05-20 Methods of treating bladder cancer

Publications (1)

Publication Number Publication Date
NZ708506A true NZ708506A (en) 2016-08-26

Family

ID=45067028

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ708506A NZ708506A (en) 2010-06-02 2011-05-20 Methods of treating bladder cancer
NZ604029A NZ604029A (en) 2010-06-02 2011-05-20 Methods of treating bladder cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ604029A NZ604029A (en) 2010-06-02 2011-05-20 Methods of treating bladder cancer

Country Status (20)

Country Link
US (2) US20130266659A1 (enExample)
EP (1) EP2575803B1 (enExample)
JP (1) JP2013527232A (enExample)
KR (1) KR20130109025A (enExample)
CN (1) CN103221042B (enExample)
AU (1) AU2011261684B2 (enExample)
BR (1) BR112012030699A2 (enExample)
CA (1) CA2801314A1 (enExample)
CO (1) CO6620019A2 (enExample)
CR (1) CR20120619A (enExample)
ES (1) ES2639038T3 (enExample)
MX (1) MX343671B (enExample)
MY (1) MY188911A (enExample)
NI (1) NI201200175A (enExample)
NZ (2) NZ708506A (enExample)
PH (2) PH12012502378A1 (enExample)
RU (1) RU2621640C2 (enExample)
SG (1) SG186109A1 (enExample)
WO (1) WO2011153009A1 (enExample)
ZA (1) ZA201208815B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI3248600T1 (sl) 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
PL1931321T3 (pl) 2005-08-31 2019-08-30 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
EP3470071A1 (en) * 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
LT2481402T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
WO2008150532A1 (en) 2007-06-01 2008-12-11 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
MX378130B (es) 2009-04-15 2025-03-10 Abraxis Bioscience Llc Métodos y composiciones de nanopartículas sin priones.
PT2552438T (pt) 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
CN105648056A (zh) 2010-05-14 2016-06-08 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
AU2011264590B2 (en) * 2010-06-07 2016-12-15 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
DK177379B1 (en) * 2012-03-29 2013-02-25 Entomopharm Aps Insect-based model to study the effect and integrity of nanoparticles on blood-brain barrier function
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US10744110B2 (en) 2013-03-12 2020-08-18 Abraxis Bioscience, Llc Methods of treating lung cancer
WO2014143613A1 (en) * 2013-03-13 2014-09-18 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
CA2903548A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术(石家庄)有限公司 一种治疗性纳米粒子及其制备方法
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
AU2016270558B2 (en) 2015-06-04 2020-08-13 Crititech, Inc. Nozzle assembly and methods for use
IL256326B2 (en) * 2015-06-29 2024-09-01 Abraxis Bioscience Llc Biomarkers for nanoparticle compositions
KR102606071B1 (ko) 2015-06-29 2023-11-27 아브락시스 바이오사이언스, 엘엘씨 상피양 세포 종양을 치료하는 방법
EP3328380A4 (en) * 2015-07-31 2019-07-24 Pharmacyclics LLC INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
CA3023274A1 (en) * 2016-05-06 2017-11-09 Taris Biomedical Llc Method of treating lower tract urothelial cancer
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3058807A1 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN110730679A (zh) 2017-06-09 2020-01-24 克里蒂泰克公司 囊内注射抗肿瘤颗粒治疗上皮囊肿
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック,インコーポレイテッド 肺障害の治療方法
EP3658153A4 (en) 2017-07-25 2021-04-21 TARIS Biomedical LLC Methods of treating tumor metastasis
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
US10792297B2 (en) 2017-11-08 2020-10-06 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
JP2021509663A (ja) * 2018-01-05 2021-04-01 クリティテック・インコーポレイテッド タキサン粒子の局所投与による膀胱癌の治療
KR102837015B1 (ko) 2018-03-20 2025-07-23 아브락시스 바이오사이언스, 엘엘씨 mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
WO2024102620A2 (en) * 2022-11-09 2024-05-16 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
EP1632259B1 (en) * 1993-07-19 2011-12-21 Angiotech Pharmaceuticals, Inc. Anti-angiogene compositions and methods of use
GB9811598D0 (en) * 1998-05-30 1998-07-29 Imp College Innovations Ltd Diagnosis and treatment of cancer
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20080255035A1 (en) * 2007-04-13 2008-10-16 Abraxis Bioscience, Inc. Sparc and methods of use thereof
CA2686736A1 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
MX2011006167A (es) * 2008-12-11 2011-07-28 Abraxis Bioscience Llc Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion.
MX340670B (es) * 2009-08-25 2016-07-20 Abraxis Bioscience Llc * Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog.

Also Published As

Publication number Publication date
ZA201208815B (en) 2014-01-29
MX2012013909A (es) 2013-02-21
MX343671B (es) 2016-11-16
EP2575803A4 (en) 2014-01-01
AU2011261684A1 (en) 2013-01-10
WO2011153009A1 (en) 2011-12-08
RU2012157805A (ru) 2014-07-20
PH12016502066A1 (en) 2019-02-04
CN103221042B (zh) 2016-02-10
CA2801314A1 (en) 2011-12-08
US20140056986A1 (en) 2014-02-27
ES2639038T3 (es) 2017-10-25
NZ604029A (en) 2015-07-31
KR20130109025A (ko) 2013-10-07
RU2621640C2 (ru) 2017-06-06
CN103221042A (zh) 2013-07-24
BR112012030699A2 (pt) 2016-09-13
EP2575803A1 (en) 2013-04-10
JP2013527232A (ja) 2013-06-27
EP2575803B1 (en) 2017-07-26
CR20120619A (es) 2014-03-21
CO6620019A2 (es) 2013-02-15
PH12012502378A1 (en) 2013-02-11
US20130266659A1 (en) 2013-10-10
MY188911A (en) 2022-01-13
AU2011261684B2 (en) 2016-09-15
NI201200175A (es) 2013-05-13
SG186109A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
NZ708506A (en) Methods of treating bladder cancer
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2012011155A (es) Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
NZ602385A (en) Methods of treating cancer
MX359413B (es) Metodos de tratamiento de carcinoma hepatocelular.
MX380318B (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
NI201200179A (es) Métodos de tratamiento contra el cáncer pancreático
CR11724A (es) Agente para tratar enfermedades
NZ745556A (en) Androgen receptor modulator and uses thereof
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MY162339A (en) Nanoparticles loaded with chemotherapeutic antitumoral drug
JP2011079858A5 (enExample)
NZ588913A (en) Liver cancer drug
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
JP2013542205A5 (enExample)
WO2014160216A3 (en) Dual targeting anticancer agents
JO3737B1 (ar) تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
HK1183814A (en) Combination therapy methods for treating proliferative diseases
NZ580225A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
TH135740A (th) การบำบัดแบบรวมด้วยองค์ประกอบอนุภาคนาโนของแทกเซน และตัวยับยั้งเฮดจ์ฮอค
HK1181667A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
UA111158C2 (uk) Спосіб комбінованої терапії для лікування проліферативних захворювань

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 MAY 2018 BY AJ PARK

Effective date: 20170227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2019 BY COMPUTER PACKAGES INC

Effective date: 20180501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2022 BY CPA GLOBAL

Effective date: 20210408

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2023 BY CPA GLOBAL

Effective date: 20220407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2024 BY CPA GLOBAL

Effective date: 20230406

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240404

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250403